Skip to content

Xanthine Oxidase and Uric Acid Origin in Preeclamptic Women

The Origin of Xanthine Oxidase and Its Metabolite, Uric Acid, in Preeclamptic Pregnant Women - A Pilot Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04463940
Enrollment
100
Registered
2020-07-09
Start date
2020-06-30
Completion date
2024-08-31
Last updated
2022-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperuricemia, Pre-Eclampsia

Keywords

Xanthine oxidase, Uric acid

Brief summary

Findings regarding the presence of xanthine oxidase and uric acid in different blood locations is important in preeclamptic women. We aim to detecting Xanthine oxidase and uric acid levels in both umbilical cord artery and vein as well as maternal blood (3 locations) in pregnant women with and without diagnosis of preeclampsia. The study population will be divided into groups matching the three locations in order to describe and compare outcome levels.

Detailed description

Significance - findings regarding the presence of xanthine oxidase and uric acid in different blood locations may provide a scientific basis for understanding the source of them in preeclamptic women. Aim - detecting Xanthine oxidase and uric acid levels in both umbilical cord artery and vein as well as maternal blood (3 locations). Methods - samples will be collected from pregnant women with and without diagnosis of preeclampsia with blood uric acid \> 6 mg/dL. Than the study population will be divided into groups matching the three locations. The investigators will describe and compare outcome levels (including Xanthine oxidase, uric acid).

Interventions

OTHERNo intervention

No intervention

Sponsors

Barzilai Medical Center
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 55 Years

Inclusion criteria

* preeclampsia and none-preeclampsia diagnosed pregnant women.

Exclusion criteria

* Known or reported kidney disease.

Design outcomes

Primary

MeasureTime frameDescription
Uric Acidthrough study completion, an average of 1 yearmg/dL

Countries

Israel

Contacts

Primary ContactYaniv Ovadia, Dr
yanivo@bmc.gov.il+ 972 (0) 8 6745220

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026